Katherine M Newton1, Susan D Reed, Katherine A Guthrie, Karen J Sherman, Cathryn Booth-LaForce, Bette Caan, Barbara Sternfeld, Janet S Carpenter, Lee A Learman, Ellen W Freeman, Lee S Cohen, Hadine Joffe, Garnet L Anderson, Joseph C Larson, Julie R Hunt, Kristine E Ensrud, Andrea Z LaCroix. 1. From the 1Group Health Research Institute, Seattle, WA; 2Departments of Obstetrics/Gynecology and Epidemiology, University of Washington School of Medicine, Seattle, WA; 3Data Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, WA; 4School of Nursing, University of Washington, Seattle, WA; 5Division of Research, Kaiser Permanente Medical Program of Northern California, Oakland, CA; 6School of Nursing, Indiana University, Indianapolis, IN; 7Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN; 8Department of Obstetrics/Gynecology, University of Pennsylvania, Philadelphia, PA; 9Massachusetts General Hospital, Boston, MA; 10Department of Medicine, VA Medical Center, Minneapolis, MN; and 11Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN.
Abstract
OBJECTIVE: This study aims to determine the efficacy of yoga in alleviating vasomotor symptoms (VMS) frequency and bother. METHODS: This study was a three-by-two factorial, randomized controlled trial. Eligible women were randomized to yoga (n = 107), exercise (n = 106), or usual activity (n = 142), and were simultaneously randomized to a double-blind comparison of ω-3 fatty acid (n = 177) or placebo (n = 178) capsules. Yoga intervention consisted of 12 weekly 90-minute yoga classes with daily home practice. Primary outcomes were VMS frequency and bother assessed by daily diaries at baseline, 6 weeks, and 12 weeks. Secondary outcomes included insomnia symptoms (Insomnia Severity Index) at baseline and 12 weeks. RESULTS: Among 249 randomized women, 237 (95%) completed 12-week assessments. The mean baseline VMS frequency was 7.4 per day (95% CI, 6.6 to 8.1) in the yoga group and 8.0 per day (95% CI, 7.3 to 8.7) in the usual activity group. Intent-to-treat analyses included all participants with response data (n = 237). There was no difference between intervention groups in the change in VMS frequency from baseline to 6 and 12 weeks (mean difference [yoga--usual activity] from baseline at 6 wk, -0.3 [95% CI, -1.1 to 0.5]; mean difference [yoga--usual activity] from baseline at 12 wk, -0.3 [95% CI, -1.2 to 0.6]; P = 0.119 across both time points). Results were similar for VMS bother. At week 12, yoga was associated with an improvement in insomnia symptoms (mean difference [yoga - usual activity] in the change in Insomnia Severity Index, 1.3 [95% CI, -2.5 to -0.1]; P = 0.007). CONCLUSIONS: Among healthy women, 12 weeks of yoga class plus home practice, compared with usual activity, do not improve VMS frequency or bother but reduce insomnia symptoms.
OBJECTIVE: This study aims to determine the efficacy of yoga in alleviating vasomotor symptoms (VMS) frequency and bother. METHODS: This study was a three-by-two factorial, randomized controlled trial. Eligible women were randomized to yoga (n = 107), exercise (n = 106), or usual activity (n = 142), and were simultaneously randomized to a double-blind comparison of ω-3 fatty acid (n = 177) or placebo (n = 178) capsules. Yoga intervention consisted of 12 weekly 90-minute yoga classes with daily home practice. Primary outcomes were VMS frequency and bother assessed by daily diaries at baseline, 6 weeks, and 12 weeks. Secondary outcomes included insomnia symptoms (Insomnia Severity Index) at baseline and 12 weeks. RESULTS: Among 249 randomized women, 237 (95%) completed 12-week assessments. The mean baseline VMS frequency was 7.4 per day (95% CI, 6.6 to 8.1) in the yoga group and 8.0 per day (95% CI, 7.3 to 8.7) in the usual activity group. Intent-to-treat analyses included all participants with response data (n = 237). There was no difference between intervention groups in the change in VMS frequency from baseline to 6 and 12 weeks (mean difference [yoga--usual activity] from baseline at 6 wk, -0.3 [95% CI, -1.1 to 0.5]; mean difference [yoga--usual activity] from baseline at 12 wk, -0.3 [95% CI, -1.2 to 0.6]; P = 0.119 across both time points). Results were similar for VMS bother. At week 12, yoga was associated with an improvement in insomnia symptoms (mean difference [yoga - usual activity] in the change in Insomnia Severity Index, 1.3 [95% CI, -2.5 to -0.1]; P = 0.007). CONCLUSIONS: Among healthy women, 12 weeks of yoga class plus home practice, compared with usual activity, do not improve VMS frequency or bother but reduce insomnia symptoms.
Authors: Garnet L Anderson; Marian Limacher; Annlouise R Assaf; Tamsen Bassford; Shirley A A Beresford; Henry Black; Denise Bonds; Robert Brunner; Robert Brzyski; Bette Caan; Rowan Chlebowski; David Curb; Margery Gass; Jennifer Hays; Gerardo Heiss; Susan Hendrix; Barbara V Howard; Judith Hsia; Allan Hubbell; Rebecca Jackson; Karen C Johnson; Howard Judd; Jane Morley Kotchen; Lewis Kuller; Andrea Z LaCroix; Dorothy Lane; Robert D Langer; Norman Lasser; Cora E Lewis; JoAnn Manson; Karen Margolis; Judith Ockene; Mary Jo O'Sullivan; Lawrence Phillips; Ross L Prentice; Cheryl Ritenbaugh; John Robbins; Jacques E Rossouw; Gloria Sarto; Marcia L Stefanick; Linda Van Horn; Jean Wactawski-Wende; Robert Wallace; Sylvia Wassertheil-Smoller Journal: JAMA Date: 2004-04-14 Impact factor: 56.272
Authors: Lorraine Dennerstein; Janet R Guthrie; Margaret Clark; Philippe Lehert; Victor W Henderson Journal: Menopause Date: 2004 Sep-Oct Impact factor: 2.953
Authors: Katherine M Newton; Janet S Carpenter; Katherine A Guthrie; Garnet L Anderson; Bette Caan; Lee S Cohen; Kristine E Ensrud; Ellen W Freeman; Hadine Joffe; Barbara Sternfeld; Susan D Reed; Sheryl Sherman; Mary D Sammel; Kurt Kroenke; Joseph C Larson; Andrea Z Lacroix Journal: Menopause Date: 2014-01 Impact factor: 3.310
Authors: Barbara Sternfeld; Andrea LaCroix; Bette J Caan; Andrea L Dunn; Katherine M Newton; Susan D Reed; Katherine A Guthrie; Cathryn Booth-LaForce; Karen J Sherman; Lee Cohen; Marlene P Freeman; Janet S Carpenter; Julie R Hunt; Melanie Roberts; Kristine E Ensrud Journal: Contemp Clin Trials Date: 2013-02-24 Impact factor: 2.261
Authors: M Shepherd-Banigan; K M Goldstein; R R Coeytaux; J R McDuffie; A P Goode; A S Kosinski; M G Van Noord; D Befus; S Adam; V Masilamani; A Nagi; J W Williams Journal: Complement Ther Med Date: 2017-08-24 Impact factor: 2.446
Authors: Crystal S Denlinger; Tara Sanft; K Scott Baker; Shrujal Baxi; Gregory Broderick; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Melissa Hudson; Nazanin Khakpour; Allison King; Divya Koura; Elizabeth Kvale; Robin M Lally; Terry S Langbaum; Michelle Melisko; Jose G Montoya; Kathi Mooney; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Jeffrey Peppercorn; M Alma Rodriguez; Kathryn J Ruddy; Paula Silverman; Sophia Smith; Karen L Syrjala; Amye Tevaarwerk; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Deborah A Freedman-Cass; Nicole R McMillian Journal: J Natl Compr Canc Netw Date: 2017-09 Impact factor: 11.908
Authors: Janet S Carpenter; James E Tisdale; Joseph C Larson; Ying Sheng; Chen X Chen; Diane Von Ah; Richard Kovacs; Susan D Reed; Rebecca C Thurston; Katherine A Guthrie Journal: Menopause Date: 2021-11-29 Impact factor: 2.953
Authors: Susan D Reed; Andrea Z LaCroix; Garnet L Anderson; Kristine E Ensrud; Bette Caan; Janet S Carpenter; Lee Cohen; Susan J Diem; Ellen W Freeman; Hadine Joffe; Joseph C Larson; Susan M McCurry; Caroline M Mitchell; Katherine M Newton; Barbara Sternfeld; Katherine A Guthrie Journal: Menopause Date: 2020-04 Impact factor: 2.953
Authors: Eric J Roseen; Hanna Gerlovin; Alexandra Femia; Jae Cho; Suzanne Bertisch; Susan Redline; Karen J Sherman; Robert Saper Journal: J Gen Intern Med Date: 2019-10-30 Impact factor: 5.128
Authors: Katherine A Guthrie; Andrea Z LaCroix; Kristine E Ensrud; Hadine Joffe; Katherine M Newton; Susan D Reed; Bette Caan; Janet S Carpenter; Lee S Cohen; Ellen W Freeman; Joseph C Larson; JoAnn E Manson; Kathy Rexrode; Todd C Skaar; Barbara Sternfeld; Garnet L Anderson Journal: Obstet Gynecol Date: 2015-08 Impact factor: 7.623
Authors: S D Reed; K M Newton; J C Larson; C Booth-LaForce; N F Woods; C A Landis; E Tolentino; J S Carpenter; E W Freeman; H Joffe; B D Anawalt; K A Guthrie Journal: Clin Endocrinol (Oxf) Date: 2016-01-26 Impact factor: 3.523